Provider Resources and Education

Amida Care Community Figures 2

Resources

Documents and Forms

Provider Manual
Amida Care Formulary
Provider Modification Form
When you are changing your practice name, address, phone numbers, e-mail, billing company, or other practice information, you only need to complete this single form and send it via:
Email: providerservices@amidacareny.org, fax: 646-786-1803, or US mail: Amida Care, Inc. c/o Provider Services 14 Penn Plaza, 2nd Floor. New York, NY 10122.
AC Fax Form for Case Submission
This form is only for Medical UM requests.
NYCDOHMH Universal Reporting Form (URF)
Communicable disease reporting and the Universal Reporting Form (URF). For any questions or to report cases immediately, call the DOH Provider Access Line at 1-866-NYC-DOH1 or, after hours, the Poison Control Center at 1-800-222-1222.

For questions about specific Amida Care policies or requirements, please contact us at: 1-800-556-0674.

Clinical Practice Guidelines

  1. Department of Health and Human Services AIDS Clinical Guidelines
  2. CDC Sexually Transmitted Diseases Treatment Guidelines
    Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report /mmwr/ December 17, 2010 / Vol. 59 / No. RR-12
  3. Amida Care Clinical Practice Guideline Adult – Asthma
  4. Amida Care Clinical Practice Guideline Adult – Diabetes
  5. Amida Care Clinical Practice Guideline Adult – Hypertension
  6. Amida Care Clinical Practice Guideline Adult – COPD
  7. NHBLI Asthma Guidelines
    National Heart, Blood and Lung Institute: Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma August 28, 2007
  8. NHBLI Prevention, Detection, and Treatment of High Blood Pressure Hypertension
    National Heart, Blood and Lung Institute: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure – Complete Report JNC7 – 2004
  9. ADA Diabetes Care Clinical Practice Recommendations
    American Diabetes Association: Diabetes Care: January 2013; 36 (Supplement 1)
    Guidelines for the Diagnosis and Management of Asthma:
  10. American Congress of Obstetricians & Gynecologists
  11. Opioid high dose limit set at 200 mg/day

Educational Opportunities

New in Cases on the Web

Immunizations for HIV-Infected Adults
Brian T. Montague, DO, MS, MPH; Steven C. Johnson, MD

Vaccination against preventable infectious diseases is a key component of comprehensive primary care for HIV-infected persons. Particularly for persons who have not yet achieved viral suppression on antiretroviral therapy or who experience incomplete or delayed immune reconstitution, the risk of infection is higher as is the risk of substantial morbidity associated with infections, including human papillomavirus (HPV)-related cancers.

Despite the acknowledged importance of vaccination, immunization rates among HIV-infected persons have historically been less than optimal. Potential barriers to adequate immunization include competing demands in the context of care visits related to other acute health concerns, practitioner belief that immunizations should be delayed until patients are stable on treatment, lack of practitioner awareness of specific immunization recommendations for HIV-infected persons, inadequate systems for tracking of immunizations, and, for some, patient resistance to immunization.

This Cases on the Web activity reviews immunization recommendations for HIV-infected persons, including the recommended vaccines and schedules, considerations for the timing of vaccinations based on immunologic status, and guidance for immunizations in the context of international travel.

On completion of this activity, the learner will be able to:

  • List the recommended immunizations for adults living with HIV infection
  • Provide specific immunization guidance based on an individual’s immunologic status and assessed risk
  • Identify contraindications to specific immunizations for persons with substantial immune deficiency
  • Identify interactions among vaccines that may impact the timing of vaccine administration
  • Provide guidance regarding immunizations appropriate for persons with HIV infection who are travelling internationally

Visit www.iasusa.org/content/immunizations-hiv-infected-adults to start learning from this new COW activity now!

Continuing Education Credits

 CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME activity is offered from July 13, 2017, to July 13, 2018. Physicians (MDs, DOs, and international equivalents) who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Other health care professionals will receive a Certificate of Participation.

Nursing Continuing Education Contact Hours

Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.

Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.

Program expires 7/12/2019.

Pharmacy Continuing Education Contact Hours

Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-17-037-H02-P

Program expires 7/12/2019.

Upcoming Live Courses From IAS-USA

 This spring, IAS–USA live courses will take place in the following cities:

Full-Day Course on HIV and Hepatitis C Virus Management
New York, NY — October 20, 2017

Half-Day Workshops on Evolving Strategies in Hepatitis C Management
Little Rock, Arkansas — September 18, 2017
Nashville, Tennessee — September 29, 2017
Louisville, Kentucky — November 17, 2017
Milwaukee, Wisconsin — November 28, 2017
Oklahoma City, Oklahoma — November 29, 2017

For detailed information, including who should attend, location, agenda, and online registration, visit www.iasusa.org.

2017 Grant Support

 This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:

For our HIV effort:

PLATINUM SUPPORTER
ViiV Healthcare

GOLD SUPPORTER
Gilead Sciences, Inc

SILVER SUPPORTERS
Bristol-Myers Squibb
Janssen Therapeutics

BRONZE SUPPORTER
Merck

For our viral hepatitis effort:

GOLD SUPPORTERS
Gilead Sciences, Inc
Merck

BRONZE SUPPORTER
AbbVie